Raze Therapeutics targets newish metabolic pathway in cancer; raises $24M
Taking a fresh approach with a metabolic pathway that spurs cancer growth, spanking-new Cambridge cancer drug startup Raze Therapeutics has just raised a $24 million Series A. The company’s already got strong venture and big pharma backing – this early round includes Atlas Ventures, MPM Capital Management, MS Ventures, Partners Innovation Fund, Astellas Venture Management and […]